{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:37:13Z","timestamp":1793824633423,"version":"4.6.1"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","award":["71019"],"award-info":[{"award-number":["71019"]}],"id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","award":["IR.TBZMED.VCR.REC.1401.307"],"award-info":[{"award-number":["IR.TBZMED.VCR.REC.1401.307"]}],"id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.biopha.2026.119118","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:09:48Z","timestamp":1770887388000},"page":"119118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Manipulation of tumor microenvironment by induction of immunogenic cell death and immune check point inhibitors for enhancing the efficacy of cancer treatments"],"prefix":"10.1016","volume":"196","author":[{"given":"Abdullah","family":"Moridikia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soheila","family":"Montazersaheb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1820-7048","authenticated-orcid":false,"given":"Ommoleila","family":"Molavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2026.119118_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.biopha.2026.119118_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.10861","article-title":"Comparison of survival among adults with rectal cancer who have undergone laparoscopic vs open surgery: a meta-analysis","volume":"5","author":"Kong","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.biopha.2026.119118_bib3","series-title":"Seminars in Cancer Biology","article-title":"Surgery-mediated tumor-promoting effects on the immune microenvironment","author":"Cheng","year":"2022"},{"issue":"2","key":"10.1016\/j.biopha.2026.119118_bib4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.biopha.2026.119118_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.960317","article-title":"Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action","volume":"12","author":"Tilsed","year":"2022","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119118_bib6","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"cell"},{"issue":"5","key":"10.1016\/j.biopha.2026.119118_bib7","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"issue":"6382","key":"10.1016\/j.biopha.2026.119118_bib8","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.biopha.2026.119118_bib9","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.biopha.2026.119118_bib10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119118_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.705361","article-title":"Immunogenic cell death induction by ionizing radiation","volume":"12","author":"Zhu","year":"2021","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119118_bib12","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.gendis.2018.05.003","article-title":"Immunogenic effects of chemotherapy-induced tumor cell death","volume":"5","author":"Wang","year":"2018","journal-title":"Genes Dis."},{"issue":"11","key":"10.1016\/j.biopha.2026.119118_bib13","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119118_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202002104","article-title":"Immune checkpoint inhibitor-based strategies for synergistic cancer therapy","volume":"10","author":"He","year":"2021","journal-title":"Adv. Healthc. Mater."},{"issue":"3","key":"10.1016\/j.biopha.2026.119118_bib15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O\u2019Donnell","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119118_bib16","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/ajt.15811","article-title":"Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: a systematic review","volume":"20","author":"d\u2019Izarny-Gargas","year":"2020","journal-title":"Am. J. Transplant."},{"issue":"11","key":"10.1016\/j.biopha.2026.119118_bib17","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J."},{"issue":"7","key":"10.1016\/j.biopha.2026.119118_bib18","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2026.119118_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2026.119118_bib20","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3892\/ol.2013.1238","article-title":"Inflammation promotes oral squamous carcinoma immune evasion via induced programmed death ligand\u20111 surface expression","volume":"5","author":"Lu","year":"2013","journal-title":"Oncol. Lett."},{"issue":"7637","key":"10.1016\/j.biopha.2026.119118_bib21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer\u2013immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.biopha.2026.119118_bib22","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1177\/1078155214538087","article-title":"Clinical evaluation of compounds targeting PD-1\/PD-L1 pathway for cancer immunotherapy","volume":"21","author":"Lu","year":"2015","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"6","key":"10.1016\/j.biopha.2026.119118_bib23","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment","volume":"8","author":"Zou","year":"2008","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119118_bib24","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.182.2.459","article-title":"CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2026.119118_bib25","article-title":"Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer","volume":"13","author":"Wang","year":"2023","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119118_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12180","article-title":"Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma","volume":"1291","author":"Wolchok","year":"2013","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"8","key":"10.1016\/j.biopha.2026.119118_bib27","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.biopha.2026.119118_bib28","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.biopha.2026.119118_bib29","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/cam4.371","article-title":"CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations","volume":"4","author":"Camacho","year":"2015","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119118_bib30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119118_bib31","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/ijms22010075","article-title":"The next-generation immune checkpoint LAG-3 and its therapeutic potential in oncology: third time\u2019sa charm","volume":"22","author":"Lecocq","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2026.119118_bib32","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","article-title":"Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and-extrinsic factors","volume":"44","author":"Pitt","year":"2016","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.biopha.2026.119118_bib33","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119118_bib34","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2057892","article-title":"Carbon ion radiotherapy triggers immunogenic cell death and sensitizes melanoma to anti-PD-1 therapy in mice","volume":"11","author":"Zhou","year":"2022","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.biopha.2026.119118_bib35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119118_bib36","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1111\/jcmm.14356","article-title":"Immunogenic cell death in cancer therapy: present and emerging inducers","volume":"23","author":"Zhou","year":"2019","journal-title":"J. Cell. Mol. Med."},{"issue":"8","key":"10.1016\/j.biopha.2026.119118_bib37","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/2326-6066.CIR-18-0940","article-title":"Systemic interferon-\u03b3 increases MHC class I expression and T-cell infiltration in cold tumors: results of a phase 0 clinical trial","volume":"7","author":"Zhang","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.biopha.2026.119118_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2867-11-33","article-title":"IFN-\u03b3, IL-17 and TGF-\u03b2 involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors","volume":"11","author":"Alshaker","year":"2011","journal-title":"Cancer Cell Int."},{"issue":"1","key":"10.1016\/j.biopha.2026.119118_bib39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1084\/jem.171.1.173","article-title":"Interleukin 2-induced proliferation of murine natural killer cells in vivo","volume":"171","author":"Biron","year":"1990","journal-title":"J. Exp. Med"},{"issue":"1","key":"10.1016\/j.biopha.2026.119118_bib40","doi-asserted-by":"crossref","DOI":"10.4110\/in.2024.24.e11","article-title":"IL-15 in T-cell responses and immunopathogenesis","volume":"24","author":"Lee","year":"2024","journal-title":"Immune Netw."},{"issue":"3","key":"10.1016\/j.biopha.2026.119118_bib41","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1158\/0008-5472.1063.65.3","article-title":"Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern","volume":"65","author":"Li","year":"2005","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119118_bib42","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1146\/annurev.immunol.19.1.423","article-title":"Interleukin-18 regulates both Th1 and Th2 responses","volume":"19","author":"Nakanishi","year":"2001","journal-title":"Annu. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119118_bib43","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrd4296","article-title":"Interleukin-21: a double-edged sword with therapeutic potential","volume":"13","author":"Spolski","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.biopha.2026.119118_bib44","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1172\/JCI80004","article-title":"From mice to humans: developments in cancer immunoediting","volume":"125","author":"Teng","year":"2015","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.biopha.2026.119118_bib45","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat. Med."},{"issue":"7261","key":"10.1016\/j.biopha.2026.119118_bib46","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nature08296","article-title":"Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance","volume":"461","author":"Elliott","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119118_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-13-311","article-title":"Expression and significance of HMGB1, TLR4 and NF-\u03baB p65 in human epidermal tumors","volume":"13","author":"Weng","year":"2013","journal-title":"BMC Cancer"},{"issue":"13","key":"10.1016\/j.biopha.2026.119118_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202207475","article-title":"Immunogenic cell death in hematological malignancy therapy","volume":"10","author":"Liu","year":"2023","journal-title":"Adv. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2026.119118_bib49","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1365-2567.2000.00121.x","article-title":"CD28, CTLA-4 and their ligands: who does what and to whom?","volume":"101","author":"Sansom","year":"2000","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.biopha.2026.119118_bib50","article-title":"Advanced nanomaterials for cancer therapy: gold, silver, and iron oxide nanoparticles in oncological applications","volume":"14","author":"Singh","year":"2025","journal-title":"Adv. Health Mater."},{"key":"10.1016\/j.biopha.2026.119118_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.02.056","article-title":"Advances in polymer nanomaterials targeting cGAS-STING pathway for enhanced cancer immunotherapy","volume":"381","author":"Peng","year":"2025","journal-title":"J. Control Release"},{"key":"10.1016\/j.biopha.2026.119118_bib52","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3389\/fimmu.2025.1726423","article-title":"Recent advances in targeting the cGAS\u2013STING pathway for immunotherapy in orthopedic diseases","volume":"16","author":"Wu","year":"2025","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119118_bib53","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2026.119118_bib54","series-title":"StatPearls","article-title":"Cancer Chemotherapy","author":"Amjad","year":"2024"},{"issue":"3","key":"10.1016\/j.biopha.2026.119118_bib55","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1158\/0008-5472.CAN-10-2788","article-title":"Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis","volume":"71","author":"Schiavoni","year":"2011","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2026.119118_bib56","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","article-title":"Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy","volume":"44","author":"Pfirschke","year":"2016","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.biopha.2026.119118_bib57","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1158\/0008-5472.CAN-09-3566","article-title":"Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity","volume":"70","author":"Aymeric","year":"2010","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119118_bib58","first-page":"151","article-title":"Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma","volume":"39","author":"Aoto","year":"2018","journal-title":"Oncol. Rep."},{"issue":"16","key":"10.1016\/j.biopha.2026.119118_bib59","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1158\/0008-5472.CAN-12-0851","article-title":"Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma","volume":"72","author":"Suzuki","year":"2012","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119118_bib60","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.2005859","article-title":"Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients","volume":"10","author":"Kroemer","year":"2021","journal-title":"Oncoimmunology"},{"issue":"12","key":"10.1016\/j.biopha.2026.119118_bib61","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1158\/1078-0432.CCR-09-2891","article-title":"Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway","volume":"16","author":"Zitvogel","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.biopha.2026.119118_bib62","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.annonc.2021.06.004","article-title":"Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer","volume":"32","author":"Sugawara","year":"2021","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119118_bib63","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1433981","article-title":"PD-1\/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer","volume":"7","author":"Dosset","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.biopha.2026.119118_bib64","first-page":"3360","article-title":"Immunogenic chemotherapy sensitizes renal cancer to immune checkpoint blockade therapy in preclinical models","volume":"23","author":"Cui","year":"2017","journal-title":"Med. Sci. Mon. Int. Med. J. Exp. Clin.l Res."},{"issue":"5","key":"10.1016\/j.biopha.2026.119118_bib65","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202201401","article-title":"Radiation-induced immunogenic cell death for cancer radioimmunotherapy","volume":"7","author":"Liu","year":"2023","journal-title":"Small Methods"},{"key":"10.1016\/j.biopha.2026.119118_bib66","doi-asserted-by":"crossref","DOI":"10.4161\/onci.28518","article-title":"Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death","volume":"3","author":"Golden","year":"2014","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.biopha.2026.119118_bib67","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.biopha.2026.119118_bib68","article-title":"Calreticulin Upregulation in Cervical Cancer Tissues From Patients After 10 Gy Radiation Therapy","volume":"8","author":"Okada","year":"2023","journal-title":"Adv. Radiat. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119118_bib69","first-page":"2064","article-title":"Tumor infiltrating lymphocytes (TILs) before and after neoadjuvant chemoradiotherapy and its clinical utility for rectal cancer","volume":"5","author":"Teng","year":"2015","journal-title":"Am. J. Cancer Res"},{"issue":"1","key":"10.1016\/j.biopha.2026.119118_bib70","doi-asserted-by":"crossref","DOI":"10.4161\/onci.22197","article-title":"Immunogenic tumor cell death induced by chemoradiotherapy in a clinical setting","volume":"2","author":"Kono","year":"2013","journal-title":"Oncoimmunology"},{"issue":"9","key":"10.1016\/j.biopha.2026.119118_bib71","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","article-title":"Role of local radiation therapy in cancer immunotherapy","volume":"1","author":"Demaria","year":"2015","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119118_bib72","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.clgc.2020.01.004","article-title":"Programmed death 1 and programmed death ligand 1 inhibitors in advanced and recurrent urothelial carcinoma: meta-analysis of single-agent studies","volume":"18","author":"Tafuri","year":"2020","journal-title":"Clin. Genitourin. Cancer"},{"issue":"7547","key":"10.1016\/j.biopha.2026.119118_bib73","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.biopha.2026.119118_bib74","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021108130","article-title":"ATP and cancer immunosurveillance","volume":"40","author":"Kepp","year":"2021","journal-title":"EMBO J."},{"issue":"12","key":"10.1016\/j.biopha.2026.119118_bib75","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","article-title":"Radiotherapy induces responses of lung cancer to CTLA-4 blockade","volume":"24","author":"Formenti","year":"2018","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119118_bib76","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119118_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1035884","article-title":"Combination of immune checkpoint inhibitors with radiation therapy in cancer: a hammer breaking the wall of resistance","volume":"12","author":"Voronova","year":"2022","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119118_bib78","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3390\/cancers13040678","article-title":"Enhance the immune checkpoint inhibitors efficacy with radiotherapy induced immunogenic cell death: A comprehensive review and latest developments","volume":"13","author":"Procureur","year":"2021","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.biopha.2026.119118_bib79","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non\u2013small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol."},{"issue":"19","key":"10.1016\/j.biopha.2026.119118_bib80","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119118_bib81","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1080\/15384047.2016.1264543","article-title":"Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone","volume":"18","author":"Koller","year":"2017","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119118_bib82","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijrobp.2022.09.052","article-title":"Phase 1 randomized trial of stereotactic body radiation therapy followed by nivolumab plus ipilimumab or nivolumab alone in advanced\/unresectable hepatocellular carcinoma","volume":"115","author":"Juloori","year":"2023","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"issue":"2","key":"10.1016\/j.biopha.2026.119118_bib83","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119118_bib84","article-title":"Safety and toxicity risks of radiotherapy combined with PD-1\/PD-L1 inhibitors: a comprehensive review","author":"Zeng","year":"2025","journal-title":"iScience"},{"issue":"2","key":"10.1016\/j.biopha.2026.119118_bib85","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.bbrc.2019.01.090","article-title":"The release and activity of HMGB1 in ferroptosis","volume":"510","author":"Wen","year":"2019","journal-title":"Biochem Biophys. Res Commun."},{"issue":"2","key":"10.1016\/j.biopha.2026.119118_bib86","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119118_bib87","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1021\/acs.jmedchem.3c01785","article-title":"Simultaneous activation of immunogenic cell death and cGAS-STING pathway by liver- and mitochondria-targeted gold(I) complexes for chemoimmunotherapy of hepatocellular carcinoma","volume":"67","author":"Li","year":"2024","journal-title":"J. Med Chem."},{"key":"10.1016\/j.biopha.2026.119118_bib88","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.semcancer.2019.03.002","article-title":"Ferroptosis is a type of autophagy-dependent cell death","volume":"66","author":"Zhou","year":"2020","journal-title":"Semin Cancer Biol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119118_bib89","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.apsb.2024.06.017","article-title":"Cyclometalated iridium(III) complex based on isoquinoline alkaloid synergistically elicits the ICD response and IDO inhibition via autophagy-dependent ferroptosis","volume":"15","author":"Lu","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.biopha.2026.119118_bib90","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s12672-025-03147-1","article-title":"Identification of a novel ferroptosis-induced immunogenic cell death related signature based on a machine learning framework in colorectal cancer","volume":"16","author":"Zhu","year":"2025","journal-title":"Discov. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119118_bib91","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s40820-025-01862-6","article-title":"Synergistic ferroptosis\u2013immunotherapy nanoplatforms: multidimensional engineering for tumor microenvironment remodeling and therapeutic optimization","volume":"18","author":"Wei","year":"2026","journal-title":"Nano-Micro Lett."},{"issue":"4","key":"10.1016\/j.biopha.2026.119118_bib92","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/imm.70049","article-title":"Photodynamic-immunotherapy synergy: decoding the spatiotemporal regulation of tumour immunogenicity for enhanced PD-1 blockade","volume":"176","author":"ChenLiu","year":"2025","journal-title":"Immunology"},{"issue":"15","key":"10.1016\/j.biopha.2026.119118_bib93","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29153704","article-title":"Recent progress in photothermal, photodynamic and sonodynamic cancer therapy: through the cGAS-STING pathway to efficacy-enhancing strategies","volume":"29","author":"Fang","year":"2024","journal-title":"Molecules"},{"issue":"18","key":"10.1016\/j.biopha.2026.119118_bib94","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/1759-7714.15325","article-title":"Enhanced systemic antitumor efficacy of PD-1\/PD-L1 blockade with immunological response induced by photodynamic therapy","volume":"15","author":"Sonokawa","year":"2024","journal-title":"Thorac. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119118_bib95","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1186\/s12967-024-05552-6","article-title":"Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy","volume":"22","author":"Su","year":"2024","journal-title":"J. Transl. Med."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226001502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226001502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:42:44Z","timestamp":1781880164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226001502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":95,"alternative-id":["S0753332226001502"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119118","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Manipulation of tumor microenvironment by induction of immunogenic cell death and immune check point inhibitors for enhancing the efficacy of cancer treatments","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119118","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119118"}}